Glycoprotein IIb/IIIa inhibitors in acute ST segment elevation myocardial infarction

Coronary Artery Disease

Volumn 10, Issue 8, 1999, Pages 567-573

  Holper, Elizabeth M ^a   Giugliano, Robert P ^a   Antman, Elliott M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angioplasty; Myocardial infarction; Percutaneous coronary; Platelet aggregation inhibitors; Platelet glycoprotein IIb IIIa complex; Thrombolytic therapy; Transluminal

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; ORBOFIBAN; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE; SIBRAFIBAN; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; XEMILOFIBAN;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; BLEEDING; BLOOD CLOT LYSIS; BLOOD VESSEL OCCLUSION; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 0032785781     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199912000-00005     Document Type: Review

References (29)

1. 1 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615-1622.
2. 2 Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 19:1065-1069.
3. 3 Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 1989; 79:920-928.
4. 4 Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82:781-791.
5. 5 ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
6. 6 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332:1553-1559.
7. 7 Coller BS, Peerschke El, Scudder LE, Sullivan CA. A murine monclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72:325-338.
8. 8 Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77:670-677. A canine model of coronary artery thrombosis was used to investigate the effects of 7E3 and t-PA, alone and in combination, on patency and reocclusion.
9. 9 Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scuder LE, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81:1284-1291.
10. 10 Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, et al. Lysis of plsminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol 1990; 16:1728-1735.
11. 11 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83:1048-1056.
12. 12 Gold HK, Grabedian SM, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation 1997; 95:1755-1759.
13. 13 Makar R, Eigler N, Goff B, Fry E, Barr L, D'Haem C, et al. Primary reperfusion in acute myocardial infarction with ReoPro and heparin: interim results of ReoMI pilot study [abstract]. J Am Coll Cardiol 1998; 2:94A.
14. 14 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961.
15. 15 Lefkovits J, Ivanhoe RJ, Califf RM, Bergelsen BA, Anderson KM, Stoner GL, et al., for the EPIC Investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 77:1045-1051. A subgroup analysis of EPIC evaluated abciximab for patients after failed thrombolysis or undergoing primary PTCA for acute myocardial infarction, and demonstrated reduced ischemic events and clinical restenosis at 6 months.
16. 16 Miller JM, Ohman EM, Schildcrout JS, Smalling RW, Betriu A, Califf RM, et al. Survival benefit of abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO III trial [abstract]. J Am Coll Cardiol 1998; 31:191A.
17. 17 Kleiman N. Ohman EM, Califf RM, George BS, Lereiakes D, Aguirre FV, et al. Profound inhibition of platelet aggregation with monoclonal antibody to 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22:381-389. This first clinical trial of m7E3 plus t-PA for acute myocardial infarction showed that glycoprotein IIb/IIIa could be administered safely 3-15 h after t-PA, and suggested possible improved vessel patency and clinical outcome.
18. 18 Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999; 99:2720-2732. The largest angiographic study to date of glycoprotein IIb/IIIa inhibitors plus thrombolytics demonstrated better angiographic outcome with combination therapy of abciximab with reduced-dose t-PA and streptokinase, suggesting a new therapeutic option for acute myocardial infarction.
19. 19 Gold HK, Kereiakes DJ, Dinsmore RE, Martin LH, Lausten D, Broderic TM, et al. A randomized, placebo-controlled, crossover trial of ReoPro alone or combined with low-dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: preliminary results [abstract]. Circulation 1997; 96 (suppl I):I-474.
20. 20 Ohman EM, Kleiman NS, Gagioch G, Worley SJ, Navetta FI, Talley JD, et al., for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 1997; 95:846-854. This angiographic trial investigated the combination of eptifibatide with full-dose, accelerated t-PA for acute myocardial infarction and demonstrated more TIMI grade 3 flow at 90 min with the highest eptifibatide dose, with no difference in severe or moderate bleeding.
21. 21 Ronner E, van Kesteren HAM, Zijnen P, Tebbe U, Molhoek P, Cuffie C, et al. Combined therapy with streptokinase and integrilin [abstract]. J Am Coll Cardiol 1998; 94A:842-843.
22. 22 The PARADIGM Investigators. Combining thrombolysis with platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antaonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998; 32:2003-2010.
23. 23 Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, et al. on behalf of the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98:734-741.
24. 24 van den Merkhof LFM, Zijlstra F, Olsson H, Grip L, Veen G, Bar FWHM, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999, 33:1528-1532.
25. 25 Morris DC. Results from late-breaking clinical trial sessions at ACCIS'99 and ACC'99. Circulation 1999; 34:1-8.
26. 26 Madan M, Tcheng JE. Coronary intervention and glycoprotein IIb/IIIa integrin blockade. Coronary Artery Dis 1999; 10:553-560.
27. 27 Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98:2695-2701.
28. 28 Ohman EM, Lincoff AM, Bode C, Bachinsky WB, Ardissino D, Betriu A, et al. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: preliminary results from the GUSTO-IV pilot (SPEED) dose-ranging trial [abstract]. Circulation 1998; 98 (suppl I):I-504.
29. 29 Goa KL, Noble S. Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999; 57;439-462.